Please ensure Javascript is enabled for purposes of website accessibility

2 Healthcare Stocks That Could Soar in 2021

By David Jagielski - Feb 25, 2021 at 6:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These companies are delivering strong results of late, and there's reason to be optimistic about what's coming next.

Healthcare is a great place to invest right now. Whether you believe that 2021 will be the last year that we're worrying much about COVID-19, or you believe that Moderna CEO Stephane Bancel is right and that this coronavirus will be around forever (though not as a pandemic-level threat), there's little doubt that there will be strong demand for quality healthcare services.

I see two healthcare stocks as having the potential to soar this year for very different reasons. American Well (AMWL -3.25%), or Amwell, could benefit from continued high demand for telehealth services, while AmerisourceBergen (ABC 0.27%) is positioned to thrive if conditions in the sector start getting back to normal and there's an uptick in pharmaceutical sales.

Doctor reviewing test results with a patient.

Image source: Getty Images.

1. The case for Amwell

Telehealth company Amwell only began trading publicly on Sept. 17. The stock is up around 30% since then (while the S&P 500 is up 15%), and there could be more gains to come. At a market cap of $7 billion, Amwell is just a fraction of the size of rival Teladoc Health, which is now worth more than $40 billion after its merger with Livongo Health. And the numbers Amwell has been generating have been phenomenal. 

When it released its third-quarter results on Nov. 12, Amwell reported 1.4 million telehealth visits for the period -- a 450% increase year over year. Revenues of $62.6 million were up by 80%. Although the company did incur a net loss of $64.6 million, poor bottom-line performances haven't exactly hurt Teladoc -- it has posted losses in each of its past five quarters.

And Amwell could accelerate its growth by making it easier for hospitals to offer telehealth services. On Feb. 18, it announced the launch of Hospital TV 100, a device that will allow hospitals to convert televisions they already have into telehealth endpoints. These can enhance social distancing and safety for health professionals while making it easier for them to keep tabs on patients.

Even though healthcare professionals are administering COVID-19 vaccines at a fairly rapid clip, it could still be some time before the pandemic is over. And in the meantime, the demand for telehealth services will remain high.

With its smaller size and a focus mainly on telehealth (Teladoc, by contrast, has been expanding into other areas, such as chronic condition management), Amwell is more of a pure-play in this area than its rival is. That could give it more of an opportunity to soar if demand for telehealth services intensifies this year.

2. The case for AmerisourceBergen

Some investors may want to hedge their bets optimistically for the possibility that the spread of COVID-19 will keep declining sharply, to the point where hospital operations will be able to start getting back to normal. One way to do that would be to invest in medical distribution company AmerisourceBergen.

For the past year, patients haven't been eager to visit physicians or hospitals due to fear of contracting the coronavirus. That has been a headwind for sales of pharmaceutical products.

In AmerisourceBergen's fiscal 2020 third quarter, which ended June 30, sales were up just 0.3% year over year, due in part to COVID-19; sales had been pulled forward as consumers stocked up on pharmaceuticals during the early stage of the pandemic. In its fiscal fourth quarter, sales growth bounced back to 7.9%. And when it released its fiscal 2021 first-quarter results on Feb. 4 (for the final three months of calendar 2020), revenues reached $52.5 billion and were growing at an even higher rate -- 9.7%. AmerisourceBergen also upgraded its guidance for fiscal 2021. Previously, it had been forecasting growth to be in the mid-single-digit percentages. Now, it expects growth in the high-single-digit percentages.

One reason to be upbeat about its growth prospects -- the company is expanding. Earlier this year, AmerisourceBergen acquired the majority of Alliance Healthcare from Walgreens Boots Alliance for $6.5 billion. The move will help expand the company's footprint, particularly in Europe, where Alliance is among the largest pharmaceutical wholesalers. While Walgreens and AmerisourceBergen work together under a strategic partnership in the U.S. and the pharmacy retailer owns close to 30% of AmerisourceBergen, the two companies focus on different areas: wholesale vs. retail.

Over the past 12 months, shares of AmerisourceBergen are up a modest 8%, while the S&P 500 has increased by 16%. However, once patient visits rise to pre-pandemic levels, pharmaceutical products should see greater demand. That alone should drive up the stock. Additionally, AmerisourceBergen's acquisition of Alliance is another reason to be bullish about its prospects in 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

American Well Corporation Stock Quote
American Well Corporation
AMWL
$4.47 (-3.25%) $0.15
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$40.87 (-0.22%) $0.09
AmerisourceBergen Corporation Stock Quote
AmerisourceBergen Corporation
ABC
$143.58 (0.27%) $0.39
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$34.35 (-2.08%) $0.73
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$142.81 (0.44%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.